Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2-breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT07570966
What this trial is testing

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals
Large-scale testing (Phase 3)UnknownNCT05253066
What this trial is testing

Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer

Who this might be right for
Breast Neoplasms
Shengjing Hospital 130
Not applicableStudy completedNCT07512063
What this trial is testing

Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 480
Not applicableActive Not RecruitingNCT06625333
What this trial is testing

A Prospective Non-interventional Study to Evaluate Clinical Outcomes of Ribociclib Combined With Endocrine Therapy in Elderly Patients With HR+HER2 - Advanced Breast Cancer in Routine Clinical Practice in Russian Federation

Who this might be right for
HR+HER2- Advanced Breast Cancer
Novartis Pharmaceuticals 329
Early research (Phase 1)Looking for participantsNCT07604571
What this trial is testing

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

Who this might be right for
Advanced HR+/HER2- Breast Cancer
Novartis Pharmaceuticals 194
Large-scale testing (Phase 3)Active Not RecruitingNCT04055493
What this trial is testing

Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Who this might be right for
Breast Cancer Female
Women's Cancer Study Group GmbH 1,684
Large-scale testing (Phase 3)Active Not RecruitingNCT03701334
What this trial is testing

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

Who this might be right for
Early Breast Cancer
Novartis Pharmaceuticals 5,101
Testing effectiveness (Phase 2)UnknownNCT06470672
What this trial is testing

Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Advanced Breast CancerHormone-receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
Fudan University 32
Testing effectiveness (Phase 2)UnknownNCT05800756
What this trial is testing

Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer

Who this might be right for
Breast Cancer
Yantai Yuhuangding Hospital 30
Testing effectiveness (Phase 2)Study completedNCT03222856
What this trial is testing

Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes

Who this might be right for
Breast Cancer
MedSIR 44
Testing effectiveness (Phase 2)Looking for participantsNCT06498154
What this trial is testing

Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy

Who this might be right for
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 200
Large-scale testing (Phase 3)Active Not RecruitingNCT05365178
What this trial is testing

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

Who this might be right for
HR-positive, HER2-negative Breast Neoplasms
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 432
Testing effectiveness (Phase 2)UnknownNCT04088110
What this trial is testing

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Who this might be right for
Breast Cancer FemaleHER2-positive Breast CancerHormone Receptor Positive Malignant Neoplasm of Breast+3 more
Fuzhou General Hospital 77
Large-scale testing (Phase 3)Not Yet RecruitingNCT06996093
What this trial is testing

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

Who this might be right for
Breast Cancer
Fudan University 2,508
Testing effectiveness (Phase 2)UnknownNCT05775575
What this trial is testing

A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer

Who this might be right for
Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 65
Testing effectiveness (Phase 2)WithdrawnNCT02853071
What this trial is testing

Efficacy and Safety of Estracyt® in Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Centre Hospitalier Universitaire de Besancon
Testing effectiveness (Phase 2)Looking for participantsNCT07117630
What this trial is testing

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

Who this might be right for
Breast Cancer
Fudan University 60
Not applicableNot Yet RecruitingNCT06871501
What this trial is testing

"Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer"

Who this might be right for
Breast Cancer
Consorzio Oncotech 1,000
Early research (Phase 1)Study completedNCT02152943
What this trial is testing

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

Who this might be right for
Advanced Malignant Solid NeoplasmEstrogen Receptor PositiveHER2/Neu Positive+10 more
M.D. Anderson Cancer Center 37
Testing effectiveness (Phase 2)Looking for participantsNCT07258108
What this trial is testing

Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors

Who this might be right for
Breast Cancer
Sun Yat-sen University 35
Next Page